Amphastar Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/04/2023

Stock Rating
14
Price Target
$44.00
Consensus
Outperform
Upside
40.98%
Analysts
0
Stock Rating
14
Upside
40.98%
Analysts
0
Price Target
$44.00

Amphastar Pharmaceuticals Stock Forecast and Price Target

Amphastar Pharmaceuticals has an average price target of $44.00 recently offered by notable experts for 2023, which would represent a potential upside of approximately 40.98% from the last closing price in February, 2023 if reached. This potential increase is based on a high estimate of $45.00 and a low estimate of $37.00. If you are not interested in AMPH stock, you may be interested in its competitors.

$44.00

40.98% Upside

Outperform
Outperform

Amphastar Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Price for Amphastar Pharmaceuticals has grown by 280.56%, going from $15.30 to $58.23. In the next year, 0 analysts estimate that Amphastar Pharmaceuticals's Fair Value will decrease by 50.10%, reaching $29.05. According to professional forecasts, in 2030, Amphastar Pharmaceuticals's Fair Value will decrease by 34.44%, reaching $38.17.

2022 Fair Value Forecast
$29.05
2023 Fair Value Forecast
$29.38
2024 Fair Value Forecast
$33.89
2025 Fair Value Forecast
$43.60
2026 Fair Value Forecast
$38.27
2027 Fair Value Forecast
$35.51
2028 Fair Value Forecast
$35.44
2029 Fair Value Forecast
$38.03
2030 Fair Value Forecast
$38.17
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$339.08 $333.19 17.97%
NOVO B Stock Forecast Novo Nordisk A/S Outperform 10
kr967.50 kr937.82 0.78%
SUNPHARMA Stock Forecast Sun Pharmaceutical Industries Outperform 18
Rp1.01k Rp845.39 2.61%
TEVA Stock Forecast Teva Pharmaceutical Industries Hold 12
$10.76 $12.04 -7.06%
HALO Stock Forecast Halozyme Therapeutics Outperform 11
$52.65 $56.22 15.86%

Amphastar Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Revenue for Amphastar Pharmaceuticals has grown by 35.80%, going from $322.36M to $437.77M. In the next year, 0 analysts estimate that Amphastar Pharmaceuticals's Revenue will decrease by 16.01%, reaching $367.70M. According to professional forecasts, in 2030, Amphastar Pharmaceuticals's Revenue will decrease by 14.23%, reaching $375.49M.

2022 Rev Forecast
$0.37B
2023 Rev Forecast
$0.36B
2024 Rev Forecast
$0.36B
2025 Rev Forecast
$0.38B
2026 Rev Forecast
$0.38B
2027 Rev Forecast
$0.37B
2028 Rev Forecast
$0.37B
2029 Rev Forecast
$0.37B
2030 Rev Forecast
$0.38B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£1.73k £29.33 -98.41%
PBH Stock Forecast Prestige Consumer Healthcare Buy 16
$60.96 $63.50 11.55%
BHC Stock Forecast Bausch Health Companies Hold 15
$7.86 $34.09 -4.58%

Amphastar Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$41.61 $35.50 -18.29%
EBS Stock Forecast Emergent BioSolutions Outperform 16
$13.97 $44.50 168.43%
ZEAL Stock Forecast Zealand Pharma A/S Outperform 8
kr117.00 kr241.83 70.94%

Amphastar Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Amphastar Pharmaceuticals's Free Cash Flow has grown, increasing from $200.00k to $70.53M – an increase of 35165.00%. 0 analysts predict Amphastar Pharmaceuticals's Free Cash Flow will decrease by 77.59% in the next year, reaching $15.81M. By 2030, professionals predict that Amphastar Pharmaceuticals's Free Cash Flow will decrease by 16.61%, to $58.81M.

2022 FCF Forecast
$0.02B
2023 FCF Forecast
$0.03B
2024 FCF Forecast
$0.05B
2025 FCF Forecast
$0.09B
2026 FCF Forecast
$0.05B
2027 FCF Forecast
$0.05B
2028 FCF Forecast
$0.05B
2029 FCF Forecast
$0.06B
2030 FCF Forecast
$0.06B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ANIP Stock Forecast ANI Pharmaceuticals Outperform 13
$44.67 $61.67 0.74%
EGRX Stock Forecast Eagle Pharmaceuticals Outperform 14
$33.75 $50.50 43.70%
AMRX Stock Forecast Amneal Pharmaceuticals Outperform 16
$2.33 $0.00 200.43%

Amphastar Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Amphastar Pharmaceuticals's Net Income has increased by 26.93%, going from $48.94M to $62.12M. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $724.78M – an increase of 1066.74%. The Amphastar Pharmaceuticals forecast is for Net Income to reach $56.43B or grow by 90744.10%.

2022 NI Forecast
$0.72B
2023 NI Forecast
$8.47B
2024 NI Forecast
$0.55B
2025 NI Forecast
$2.86B
2026 NI Forecast
$15.00B
2027 NI Forecast
$79.29B
2028 NI Forecast
$15.10B
2029 NI Forecast
$28.34B
2030 NI Forecast
$56.43B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
XERS Stock Forecast Xeris Pharmaceuticals Buy 6
$1.18 $0.00 408.47%
ENDP Stock Forecast Endo International Underperform 14
$0.41 $0.00 143.90%
ASRT Stock Forecast Assertio Holdings Outperform 8
$4.10 $5.83 46.34%

Amphastar Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

Amphastar Pharmaceuticals's EBITDA has increased by 426.67% In the last two years, going from $18.07M to $95.17M. For the following year, the 0 analysts predict that Amphastar Pharmaceuticals's EBITDA will drop by 58.31%, reaching $39.67M. In 2030, the professionals' prediction is that AMPH's EBITDA will decrease by 35.84%, reaching $61.06M.

2022 EBITDA Forecast
$0.04B
2023 EBITDA Forecast
$0.04B
2024 EBITDA Forecast
$0.05B
2025 EBITDA Forecast
$0.07B
2026 EBITDA Forecast
$0.06B
2027 EBITDA Forecast
$0.06B
2028 EBITDA Forecast
$0.06B
2029 EBITDA Forecast
$0.06B
2030 EBITDA Forecast
$0.06B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
OPNT Stock Forecast Opiant Pharmaceuticals Buy 10
$10.44 $43.00 287.93%
LCI Stock Forecast Lannett Company Hold 10
$0.62 $2.25 262.90%
ACOR Stock Forecast Acorda Therapeutics - 5
$0.45 $5.00 11.11%

Amphastar Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Amphastar Pharmaceuticals's EBIT has grown, increasing from $-40.00k to $71.69M – a growth of 179325.00%. In the following year, the 0 analysts surveyed believe that Amphastar Pharmaceuticals's EBIT will decrease by 87.78%, reaching $8.76M. Over the next nine years, experts anticipate that Amphastar Pharmaceuticals's EBIT will grow at a rate of 83.01%.

2022 EBIT Forecast
$0.01B
2023 EBIT Forecast
$0.02B
2024 EBIT Forecast
$0.07B
2025 EBIT Forecast
$0.21B
2026 EBIT Forecast
$0.07B
2027 EBIT Forecast
$0.09B
2028 EBIT Forecast
$0.12B
2029 EBIT Forecast
$0.17B
2030 EBIT Forecast
$0.13B

Amphastar Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, EPS for Amphastar Pharmaceuticals has grown by 280.56%, going from $0.36 to $1.37. In the next year, 0 analysts estimate that Amphastar Pharmaceuticals's EPS will decrease by 50.10%, reaching $0.68. According to professional forecasts, in 2030, Amphastar Pharmaceuticals's EPS will decrease by 34.44%, reaching $0.90.

2022 EPS Forecast
$0.68
2023 EPS Forecast
$0.69
2024 EPS Forecast
$0.80
2025 EPS Forecast
$1.03
2026 EPS Forecast
$0.90
2027 EPS Forecast
$0.84
2028 EPS Forecast
$0.83
2029 EPS Forecast
$0.89
2030 EPS Forecast
$0.90